Senseonics (NYSE:SENS) Upgraded at StockNews.com

StockNews.com upgraded shares of Senseonics (NYSE:SENSFree Report) to a sell rating in a research note released on Friday morning.

Senseonics Trading Down 1.4 %

NYSE SENS opened at $0.52 on Friday. The firm has a market cap of $277.81 million, a P/E ratio of -4.76 and a beta of 0.87. The company has a current ratio of 7.53, a quick ratio of 7.03 and a debt-to-equity ratio of 1.15. Senseonics has a 12 month low of $0.46 and a 12 month high of $1.05. The firm has a 50 day moving average of $0.59.

Senseonics (NYSE:SENSGet Free Report) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01. Senseonics had a negative return on equity of 146.90% and a negative net margin of 270.13%. The company had revenue of $8.00 million during the quarter, compared to the consensus estimate of $7.62 million. As a group, sell-side analysts predict that Senseonics will post -0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Senseonics

Large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new position in Senseonics during the 2nd quarter worth $1,358,000. State Street Corp increased its position in Senseonics by 11.6% during the 2nd quarter. State Street Corp now owns 14,097,923 shares of the company’s stock worth $14,521,000 after buying an additional 1,467,601 shares during the period. Vanguard Group Inc. increased its position in Senseonics by 6.5% during the 1st quarter. Vanguard Group Inc. now owns 21,431,413 shares of the company’s stock worth $42,221,000 after buying an additional 1,306,932 shares during the period. BlackRock Inc. increased its position in Senseonics by 3.3% during the 3rd quarter. BlackRock Inc. now owns 31,324,927 shares of the company’s stock worth $41,350,000 after buying an additional 1,003,971 shares during the period. Finally, AXA S.A. increased its position in Senseonics by 116.8% during the 1st quarter. AXA S.A. now owns 1,134,900 shares of the company’s stock worth $806,000 after buying an additional 611,500 shares during the period. Institutional investors own 12.36% of the company’s stock.

About Senseonics

(Get Free Report)

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.

Read More

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.